

ACE Immunoid™ Neoantigen Prediction: At-a-glance



ACE Immunoid is an analytically-validated whole exome and transcriptome sequencing platform using matched tumor and normal samples, developed for use with our RUO neoantigen prediction analysis pipeline. With optimized processes and dedicated project management support, Personalis offers a one-stop solution for immuno-oncology research and clinical trials.



CLIA
Validated

Augmented Whole Exome & Transcriptome

Across
>8,000
Biomedically
relevant genes



2-Week
Turnaround

200x Coverage

**Matched
Tumor/
Normal**
Analysis



50 ng
minimum
sample input

Custom Bioinformatics Reporting:

- Neoantigen prediction
- Tumor mutational burden
- Comprehensive tumor profiling
- HLA-typing
- MHC binding prediction



Exome*



Transcriptome*



Neoantigen Prediction‡
96% Sensitivity

* At 10% mutant allele frequencies for small variants

‡ 22/23 experimentally-validated neoantigens correctly predicted

Ready to accelerate your cancer vaccine development?
To learn more, contact us at info@personalis.com